PathAI is evolving pathology using machine learning and deep learning techniques to drive faster more accurate diagnosis of disease.
Introduced by Marcus Dahllof, Associate Program Director, MIT Startup Exchange; Cliff Reid, PhD, CEO, Travera; Todd Gierahn, PhD, Cofounder, Honeycomb; Laura Indolfi, PhD, CEO & Cofounder, PanTher Therapeutics; Ulrik Nielsen, PhD, CEO & Cofounder, Torque; Jason Norris, Cofounder, Elektrofi; Patrick Stern, PhD, CEO & Founder, Sextant; Carlos Castro-Gonzalez, PhD, CEO & Cofounder, Leuko Labs; and Alec Nielsen, PhD, Cofounder, Asimov.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
Interpretable AI co-founders, Jack Dunn and Daisy Zhuo
James J. Collins, Termeer Professor of Medical Engineering & Science, MIT & co-founder of Enbiotix, Synlogic, and multiple other startups fostered in the Collins lab, including Sample6.